Diffuse Large B-cell Lymphoma Activated B-cell Type
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma Activated B-cell Type.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma [Phase 1]
Phase 1 clinical trial update for tegavivint in relapsed or refractory diffuse large B-cell lymphoma, with ongoing recruitment.
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma,…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]
Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBC…
-
CLINICAL_TRIALS trial_result · 2020-07-29Clinical Trial Update: Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 study of acalabrutinib (ACP-196), a BTK inhibitor, in de novo activated B-cell diffuse large B-cell lymphoma (ABC DLBCL) completed…